HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Franceschino, A. Articles by Gambacorti-Passerini, C. PubMed PubMed Citation Articles by Franceschino, A. Articles by Gambacorti-Passerini, C.

Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib

¹ University of Milano Bicocca, Monza, Italy; San Gerardo Hospital, Monza, Italy;
² Department of Oncology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada. Key words: CML, tyrosine kinase inhibitor, long term side effects, CK Funding: AIRC, NCIC, AIFA, CARIPLO

Correspondence: Carlo Gambacorti-Passerini, Professor of Internal Medicine and Oncology/University of Milano Bicocca, Italy and JGH, McGill University, Montreal, Canada., E-mail: carlo.gambacorti{at}unimib.it

Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values.